Literature DB >> 28421242

CT features of hepatic metastases from hepatoid adenocarcinoma.

Min-Yung Chang1,2,3, Hye Jin Kim1,2,4, Seung Hyun Park1,2, Hyunki Kim5, Dong Kyu Choi6, Joon Seok Lim1,2, Mi-Suk Park1,2, Myeong-Jin Kim1,2, Honsoul Kim7,8.   

Abstract

PURPOSE: The purpose of this study was to report the imaging presentation of hepatic metastases from hepatoid adenocarcinoma (HAC).
METHODS: We retrospectively identified 11 patients (10 men and 1 woman; median age 66) with HAC liver metastasis who underwent contrast-enhanced computed tomography (CT) which included arterial phase and portal venous phase. Two radiologists analyzed the imaging parameters, which included the enhancement pattern on arterial and portal phase images, necrosis, venous thrombi, and overall imaging diagnosis, and arrived at a consensus.
RESULTS: On arterial phase, the liver lesions had global hyper-enhancement (n = 0), heterogeneous hyper-enhancement (63.6%; n = 7/11), peripheral hyper-enhancement (n = 0), iso-enhancement (n = 0/11), or hypo-enhancement (36.4%; n = 4/11). On portal venous phase, homogenous hypo-enhancement (18.2%; n = 2/11) and heterogenous hypo-enhancement (81.8%; n = 9/11) were observed. Venous thromboses occurred in four patients (36.4%; n = 4/11). The overall imaging diagnoses were "HCC-like" in seven patients (63.6%; n = 7/11), "indeterminable" in 1 patient (9.1%; n = 1/11), and "HCC-unlike" in three patients (27.3%; n = 3/11).
CONCLUSIONS: The imaging features of HAC liver metastasis were varied. Arterial phase enhancement coupled with venous phase washout (resembling HCC imaging features) was a major finding, but arterial phase hypo-enhancement (distinct from HCC imaging features) was also frequently encountered.

Entities:  

Keywords:  CT; Hepatocellular carcinoma; Hepatoid adenocarcinoma; Liver metastasis

Mesh:

Substances:

Year:  2017        PMID: 28421242     DOI: 10.1007/s00261-017-1150-3

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  5 in total

1.  Ectopic hepatocellular carcinoma manifesting multiple abdominal masses: A case report.

Authors:  RenAn Jin; Qingsong Yu; Xiao Liang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

2.  Hepatoid Adenocarcinoma of the Rectum With Liver Metastasis in a Patient With Ulcerative Colitis.

Authors:  Alexander N Levy; Rachel Ackerman; Osman Yilmaz; Caroline Jouhourian; Manish Tandon; Michael W Winter
Journal:  ACG Case Rep J       Date:  2019-05-17

Review 3.  Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives.

Authors:  Jon Arne Søreide
Journal:  Ther Clin Risk Manag       Date:  2019-12-23       Impact factor: 2.423

Review 4.  Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments.

Authors:  Ruolan Xia; Yuwen Zhou; Yuqing Wang; Jiaming Yuan; Xuelei Ma
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

5.  Computed Tomography Features and Clinical Prognostic Characteristics of Hepatoid Adenocarcinoma of the Stomach.

Authors:  Wen-Peng Huang; Li-Ming Li; Jing Li; Jun-Hui Yuan; Ping Hou; Chen-Chen Liu; Yi-Hui Ma; Xiao-Nan Liu; Yi-Jing Han; Pan Liang; Jian-Bo Gao
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.